Purdue Pharma and the Sackler family will be protected from opioid litigation until April 8, 2020. Bankruptcy Judge Robert Drain made the decision in order to provide the pharmaceutical company time to attempt to reach a legal settlement that may be work $10 billion.
The Judge will approve an order extending the stay on more than 2,600 lawsuits that accuse OxyContin maker, Purdue, and the Sacklers of adding to the opioid crisis.
During the stay, Purdue and the Sacklers have voiced plans to share information with those who have filed suit.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Purdue filed for bankruptcy in September in an effort to group all suits into one court. It will now be evaluated through the discovery process with the pharmaceutical maker and the Sacklers.
Those representing dissenting states and municipalities have objected to the temporary injunction, which includes the Sackler family, who have not filed for personal bankruptcy. Some, however, have reached a deal with Purdue, agreeing to voluntarily comply with the temporary injection. The agreement allows those states to change their decision later and fight the injunction.